<DOC>
	<DOCNO>NCT00303992</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving trastuzumab together irinotecan may kill tumor cell . PURPOSE : This phase II trial study well give trastuzumab together irinotecan work treat patient HER2/neu positive metastatic breast cancer .</brief_summary>
	<brief_title>Trastuzumab Irinotecan Treating Patients With HER2/Neu Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall objective response-rate ( partial complete ) stable disease rate patient HER2/neu positive metastatic breast cancer treat combination irinotecan hydrochloride trastuzumab ( Herceptin® ) prior first- second-line therapy trastuzumab combine chemotherapeutic agent . Secondary - Determine toxicity combination regimen . - Determine duration response time disease progression patient treat combination . - Document development brain metastasis progression know metastasis patient treat regimen . OUTLINE : Patients receive trastuzumab ( Herceptin® ) IV 30-90 minute day 1 , 8 , 15 , 22 irinotecan hydrochloride IV 30-60 minute day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic breast carcinoma Received 13 prior chemotherapy regimens metastatic disease Documented progressive disease Repeated course chemotherapy agent alone combination consider single regimen Prior trastuzumab ( Herceptin® ) alone chemotherapy allow Other biologic agent consider chemotherapy regimen Measurable disease Patients boneonly disease evaluable tumor marker ( e.g. , CA153 , CEA , CA27.29 ) eligible Patients must prior evidence correlation disease activity change tumor marker level Confirmation HER2/neu status positive test gene amplification fluorescence situ hybridization 3+ immunohistochemistry Brain metastases allow follow criterion meet : Brain metastases previously treat currently stable document head CT scan contrast MRI within 4 week study entry Patients exist brain metastasis stability document prior image ≥ 8 week baseline scan Hormonereceptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status ≤ 2 Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Life expectancy ≥ 12 week No history congestive heart failure Documented ejection fraction ≥ 45 % MUGA scan echocardiogram within 1 month study entry Total bilirubin &lt; 3 time upper limit normal ( ULN ) AST &lt; 3 time ULN ( 5 time ULN due liver involvement ) Creatinine &lt; 1.5 time ULN No history serious adverse event relate trastuzumab Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No severe , concurrent illness would prevent compliance study protocol No chronic severe diarrheal illness No history Gilbert 's disease know deficiency glucuronidation No recent current history alcoholism acute viral hepatitis PRIOR CONCURRENT THERAPY : See Disease Characteristics No chemotherapy hormonal therapy within past 2 week Prior concurrent bisphosphonates allow No prior irinotecan ( camptothecins allow ) No concurrent radiotherapy No ongoing treatment investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>